Overexpression and mutation of p53 in epithelial ovarian cancer - PubMed (original) (raw)
. 1991 Jun 1;51(11):2979-84.
Affiliations
- PMID: 2032235
Overexpression and mutation of p53 in epithelial ovarian cancer
J R Marks et al. Cancer Res. 1991.
Abstract
We examined p53 expression in 107 epithelial ovarian cancers with immunohistochemical techniques using monoclonal antibody PAb1801. High level expression of nuclear p53 protein was detected in the malignant epithelium in 54 (50%) of these cancers. Expression of p53 protein was undetectable in 13 benign gynecological tissues. p53 mRNA from three cancers that overexpressed the protein were sequenced and point mutations which altered the coding sequence of the highly conserved region of the gene were found in each case. Three cancers with undetectable protein levels also were sequenced and were found to be wild-type through the same region of the gene. As in other cancers, overexpression of the p53 protein in ovarian cancer appears to correlate closely with the presence of mutation in the p53 gene. p53 overexpression did not correlate with stage, histological grade, or the ability to perform optimal cytoreductive surgery. A significant correlation (P = 0.04) was observed between p53 overexpression and aneuploidy in advanced stage (III/IV) disease. There was no significant relationship between overall survival and p53 expression. Since mutation and overexpression of p53 are common in epithelial ovarian cancers, further studies are warranted to clarify the role of p53 in ovarian tumorigenesis.
Similar articles
- Overexpression and mutation of p53 in endometrial carcinoma.
Kohler MF, Berchuck A, Davidoff AM, Humphrey PA, Dodge RK, Iglehart JD, Soper JT, Clarke-Pearson DL, Bast RC Jr, Marks JR. Kohler MF, et al. Cancer Res. 1992 Mar 15;52(6):1622-7. Cancer Res. 1992. PMID: 1540970 - Mutation and overexpression of p53 in early-stage epithelial ovarian cancer.
Kohler MF, Kerns BJ, Humphrey PA, Marks JR, Bast RC Jr, Berchuck A. Kohler MF, et al. Obstet Gynecol. 1993 May;81(5 ( Pt 1)):643-50. Obstet Gynecol. 1993. PMID: 8469448 - Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma.
Leitao MM, Soslow RA, Baergen RN, Olvera N, Arroyo C, Boyd J. Leitao MM, et al. Gynecol Oncol. 2004 May;93(2):301-6. doi: 10.1016/j.ygyno.2004.01.043. Gynecol Oncol. 2004. PMID: 15099937 - A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors.
Kmet LM, Cook LS, Magliocco AM. Kmet LM, et al. Cancer. 2003 Jan 15;97(2):389-404. doi: 10.1002/cncr.11064. Cancer. 2003. PMID: 12518363 Review. - [Classical and novel molecular prognostic factors in ovarian cancers].
Zasławski R, Surowiak P, Zabel M. Zasławski R, et al. Pol Merkur Lekarski. 2005 Dec;19(114):823-7. Pol Merkur Lekarski. 2005. PMID: 16521433 Review. Polish.
Cited by
- Oxyresveratrol Enhances the Anti-Cancer Effect of Cisplatin against Epithelial Ovarian Cancer Cells through Suppressing the Activation of Protein Kinase B (AKT).
Thaklaewphan P, Wikan N, Potikanond S, Nimlamool W. Thaklaewphan P, et al. Biomolecules. 2024 Sep 9;14(9):1140. doi: 10.3390/biom14091140. Biomolecules. 2024. PMID: 39334906 Free PMC article. - Resveratrol Enhances Cytotoxic Effects of Cisplatin by Inducing Cell Cycle Arrest and Apoptosis in Ovarian Adenocarcinoma SKOV-3 Cells through Activating the p38 MAPK and Suppressing AKT.
Hankittichai P, Thaklaewphan P, Wikan N, Ruttanapattanakul J, Potikanond S, Smith DR, Nimlamool W. Hankittichai P, et al. Pharmaceuticals (Basel). 2023 May 17;16(5):755. doi: 10.3390/ph16050755. Pharmaceuticals (Basel). 2023. PMID: 37242538 Free PMC article. - Immunotherapeutic Approaches in Ovarian Cancer.
Yoon H, Kim A, Jang H. Yoon H, et al. Curr Issues Mol Biol. 2023 Feb 2;45(2):1233-1249. doi: 10.3390/cimb45020081. Curr Issues Mol Biol. 2023. PMID: 36826026 Free PMC article. Review. - Discovery of new therapeutic targets in ovarian cancer through identifying significantly non-mutated genes.
Al-Farsi H, Al-Azwani I, Malek JA, Chouchane L, Rafii A, Halabi NM. Al-Farsi H, et al. J Transl Med. 2022 May 26;20(1):244. doi: 10.1186/s12967-022-03440-5. J Transl Med. 2022. PMID: 35619151 Free PMC article. - Beyond the snapshot: optimizing prognostication and prediction by moving from fixed to functional multidimensional cancer pathology.
Kramer C, Vreeswijk M, Thijssen B, Bosse T, Wesseling J. Kramer C, et al. J Pathol. 2022 Jul;257(4):403-412. doi: 10.1002/path.5915. Epub 2022 May 23. J Pathol. 2022. PMID: 35438188 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous